Mitchell & Pahl Private Wealth’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $692K | Buy |
4,560
+717
| +19% | +$109K | 0.31% | 112 |
|
|
2025
Q1 | $578K | Buy |
3,843
+240
| +7% | +$36.1K | 0.27% | 118 |
|
|
2024
Q4 | $665K | Buy |
3,603
+292
| +9% | +$53.9K | 0.31% | 107 |
|
|
2024
Q3 | $652K | Buy |
3,311
+157
| +5% | +$30.9K | 0.3% | 117 |
|
|
2024
Q2 | $652K | Buy |
3,154
+62
| +2% | +$12.8K | 0.34% | 104 |
|
|
2024
Q1 | $838K | Buy |
3,092
+133
| +4% | +$36K | 0.44% | 85 |
|
|
2023
Q4 | $700K | Buy |
2,959
+10
| +0.3% | +$2.36K | 0.4% | 95 |
|
|
2023
Q3 | $578K | Buy |
2,949
+462
| +19% | +$90.5K | 0.34% | 104 |
|
|
2023
Q2 | $523K | Buy |
2,487
+204
| +9% | +$42.9K | 0.32% | 109 |
|
|
2023
Q1 | $461K | Buy |
2,283
+52
| +2% | +$10.5K | 0.29% | 116 |
|
|
2022
Q4 | $486K | Buy |
2,231
+173
| +8% | +$37.7K | 0.32% | 109 |
|
|
2022
Q3 | $405K | Buy |
2,058
+111
| +6% | +$21.8K | 0.3% | 113 |
|
|
2022
Q2 | $417K | Buy |
1,947
+719
| +59% | +$154K | 0.29% | 110 |
|
|
2022
Q1 | $349K | Buy |
1,228
+175
| +17% | +$49.7K | 0.22% | 131 |
|
|
2021
Q4 | $397K | Buy |
1,053
+257
| +32% | +$96.9K | 0.25% | 119 |
|
|
2021
Q3 | $328K | Buy |
796
+15
| +2% | +$6.18K | 0.24% | 126 |
|
|
2021
Q2 | $289K | Buy |
+781
| New | +$289K | 0.21% | 128 |
|